# Eton Pharmaceuticals, Inc. (ETON) FY2026 Q2 P&L / Income Statement

- Company: Eton Pharmaceuticals, Inc. (ETON)
- Period: 2026-04-01 to 2026-06-30
- Filing: Q2 FY2026 10-Q, filed 2026-08-13, accession number 0001437749-26-027684
- Page: https://plicit.ai/financials/eton/fy2026-q2-income-statement
- Chart image: https://plicit.ai/charts/eton-fy2026-q2-income-statement-sankey.png

## Chart details: Revenue by Product and Service

Income statement for 2026-04-01 through 2026-06-30. View: Product and service. Revenue and costs use their disclosed categories.

- **Total net revenues**: 37,589,000 US dollars
- **Product sales and royalties, net**: 12,176,000 US dollars
- **Gross profit**: 25,413,000 US dollars
- **Total operating expenses**: 12,619,000 US dollars
- **Income (loss) from operations**: 12,794,000 US dollars
- **Other income (expense), net (calculated)**: negative 1,076,000 US dollars
- **Income (loss) before income tax expense**: 11,718,000 US dollars
- **Income tax expense**: 140,000 US dollars
- **Net income (loss)**: 11,578,000 US dollars
- **Product revenue**: 37,589,000 US dollars
- **License revenue**: 0 US dollars
- **Product cost of revenue**: 12,176,000 US dollars
- **License cost of revenue**: 0 US dollars
- **General and administrative**: 11,626,000 US dollars
- **Research and development**: 993,000 US dollars

### Chart connections

- Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
- Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.